Gene Expression Panel for Acute Graft Rejection Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical procedures for organ transplantation face challenges in early detection of acute graft rejection, leading to potential organ loss and unnecessary immunosuppressive drug toxicity, as existing methods lack reliable non-invasive biomarkers for predicting and diagnosing rejection.
Innovation Solution
Monitoring of gene expression levels in blood or biopsy samples for specific genes such as NKTR, MAPK9, DUSP1, PBEF1, PSEN1, CFLAR, RNF-130, IFNGR1, ITGAX, and RYBP to predict, diagnose, and characterize acute rejection responses, allowing for personalized immunosuppressive regimens and timely intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive therapy is used to prevent graft rejection, then graft survival is improved, but drug toxicity increases
Solution Approach 1:
The gene expression panel enables early detection of acute rejection before clinical symptoms appear, allowing immunosuppressive therapy to be adjusted proactively. By identifying rejection risk in advance through biomarker analysis, clinicians can intensify or de-escalate immunosuppression timing-wise, preventing graft loss while minimizing unnecessary prolonged drug exposure and associated toxicity.
Solution Approach 2:
The invention implements a feedback mechanism by continuously monitoring gene expression levels (NKTR, MAPK9, DUSP1, PBEF1, PSEN1) in patient samples. This real-time molecular feedback allows dynamic adjustment of immunosuppressive regimens - increasing dosage when rejection is detected early, or reducing dosage when rejection is absent - thereby optimizing graft survival while minimizing drug toxicity through precision medicine.
2Reliability
If aggressive immunosuppression is applied to treat acute rejection, then graft survival is improved, but drug toxicity increases
Solution Approach 1:
The gene expression panel enables partial action by selectively applying aggressive immunosuppression only when and where needed - specifically when acute rejection is detected through biomarker analysis. Rather than universally applying high-dose immunosuppression to all transplant patients, the system identifies only those with molecular evidence of rejection, administering intensive therapy precisely to the subset of patients who need it, thereby improving graft survival in responsive patients while minimizing toxicity in those who don't require such aggressive treatment.
3Loss of time
If early detection of acute rejection is achieved, then treatment timing is improved, but diagnostic accuracy requirements increase
Solution Approach 1:
The invention segments the complex immune rejection process into distinct molecular signatures by analyzing specific gene expression patterns (NKTR, MAPK9, DUSP1, PBEF1, PSEN1). Rather than attempting a single undifferentiated diagnosis, the panel divides rejection detection into specific biomarker measurements, each contributing to the overall diagnostic accuracy. This segmentation allows early detection through multiple independent molecular indicators, reducing the burden on any single test while maintaining high diagnostic precision.
Solution Approach 2:
The diagnostic approach uses a composite biomarker panel combining multiple gene expression measurements rather than relying on a single marker. This composite diagnostic system integrates signals from five different genes involved in the rejection pathway, creating a more robust and accurate early detection tool. The composite nature of the panel compensates for individual marker variability, achieving high diagnostic accuracy for early rejection detection through the combined information from multiple molecular sources.
4Ease of operation
If non-invasive monitoring methods are used, then patient comfort is improved, but measurement reliability may decrease
Solution Approach 1:
The invention uses circulating biomarkers in blood or urine samples as intermediary molecules that reflect the state of the graft without requiring direct tissue sampling. These molecular intermediaries (gene expression products in accessible body fluids) serve as proxies for the actual rejection process occurring in the transplanted organ, enabling non-invasive monitoring while maintaining diagnostic reliability through the specific molecular signatures detected by the panel.
Data Source
AI summary
Methods are provided for monitoring a subject having a graft for an acute rejection (AR) response, e.g., to predict, to diagnose, and/or to characterize an AR response. In practicing the subject methods, the expression level of at least one gene in a sample from the subject, e.g., a blood or biopsy sample, is evaluated, e.g., at the nucleic acid and/or protein level, to monitor the subject. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.